The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Hemolytic and uremic syndrome (HUS). See also under Xaf
Publications
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
Cancer 1999 May 01;85;2023-32 — 1999 May 01 — 2023-32
Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations.
British medical journal (Clinical research ed.) 1982 May 15;284;1432-4 — 1982 May 15 — 1432-4
Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985 May;3;723-34 — 1985 May — 723-34
Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1987 Jan;8;33-41 — 1987 Jan — 33-41
A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.
Cancer 1986 Oct 01;58;1428-36 — 1986 Oct 01 — 1428-36